SEC. 506G. RECALL AUTHORITY.
``(a) Order To Cease Distribution of Drug; Notification of Health
Professionals.--
``(1) In general.--If the Secretary finds that a drug
intended for human use may constitute a threat to the public
health, the Secretary shall issue an order requiring the
appropriate person (including the manufacturers, importers,
distributors, or retailers of the drug)--
``(A) to immediately cease distribution of the
drug; and
``(B) to immediately notify health professionals of
the order and to instruct such professionals to cease
administering, distributing, selling, or prescribing
the drug.
``(2) Informal hearing.--An order under paragraph (1) shall
provide the person subject to the order with an opportunity for
an informal hearing, to be held not later than 10 days after
the date of the issuance of the order, on the actions required
by the order and on whether the order should be amended to
require a recall of the drug involved. If, after providing an
opportunity for such a hearing, the Secretary determines that
inadequate grounds exist to support the actions required by the
order, the Secretary shall vacate the order.
``(b) Order To Recall Drug.--
``(1) In general.--If, after providing an opportunity for
an informal hearing under subsection (a)(2), the Secretary
determines that the order should be amended to include a recall
of the drug with respect to which the order was issued, the
Secretary shall, except as provided in paragraphs (2) and (3),
amend the order to require a recall. The Secretary shall
specify a timetable in which the drug recall will occur and
shall require periodic reports to the Secretary describing the
progress of the recall.
``(2) Certain actions.--An amended order under paragraph
(1)--
``(A) shall not require recall of a drug from
individuals; and
``(B) shall provide for notice to individuals
subject to the risks associated with the use of the
drug.
``(3) Assistance of health professionals.--In providing the
notice required by paragraph (2)(B), the Secretary may use the
assistance of health professionals who administered the drug
involved to individuals or prescribed the drug for individuals.
If a significant number of such individuals cannot be
identified, the Secretary shall notify such individuals
pursuant to section 705(b).''.
SEC. 7. AUTHORITY TO ISSUE SUBPOENAS WITH RESPECT TO PREVENTING THREATS
TO THE PUBLIC HEALTH.
Section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
333(a)) is amended by adding at the end the following subsection:
``(h) The Secretary and the Attorney General shall develop and
implement a procedure through which the Chief Counsel in the Food and
Drug Administration is authorized to issue subpoenas regarding
investigations under this Act of acts or omissions that may constitute
a threat to the public health, including investigations of alleged
violations to which paragraph (3) or (4) of subsection (a) apply and
alleged violations with respect to which the Secretary is considering
the use of authorities under section 304.''.
<all>
Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Wednesday, January 7, 2015
Proposed FDA Recall Authority in H.R.5874 - Counterfeit Drug Enforcement Act of 2014 is Needed. Here is the language:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment